(99m)Tc-3P-RGD2 molecular imaging targeting integrin α(v)β(3) in head and neck squamous cancer xenograft.

(99m)Tc-3P-RGD2 and SPECT/CT were valuable tools for selecting patient likely benefit from integrin α(v)β(3) blocking therapy. To evaluate the feasibility of (99m)Tc-3P-RGD2 imaging to detect head and neck squamous cell carcinoma, (99m)Tc-3P-RGD2 was prepared and the relationship between its accumulation and integrin α(v)β(3) expression in nude mice bearing HEP-2 or CNE-1 carcinoma xenograft were analyzed. This study demonstrated that (99m)Tc-3P-RGD2, with high affinity to integrin α(v)β(3), will provide basis for α(v)β(3) involved individual therapy.